source
- Biokin's EGFR-HER3 bispecific ADC succeeds in late-stage Chinese lung cancer trialChinese biotech Biokin announced that its EGFRxHER3 bispecific antibody-drug conjugate met its primary endpoint in a late-stage trial in a genetically defined subset of non-small cell lung cancer (…
- J&J MedTech secures FDA 510(k) clearance for Monarch Quest 3 bronchoscopy software updateJohnson & Johnson MedTech announced that its Monarch bronchoscopy robot has received FDA 510(k) clearance for the latest software version, Monarch Quest 3. This marks the fourth major software laun…